AK-7
AK-7 is a specialized research chemical designed to cross the blood-brain barrier and block SIRT2, a cytoplasmic enzyme that alters cellular transport networks. By preventing SIRT2 from modifying alpha-tubulin, the compound reinforces the axonal tracks required for healthy neuronal function. In preclinical models of Parkinson's disease, doses of 20 milligrams per kilogram protect vulnerable dopaminergic neurons from toxicity and restrict the harmful aggregation of alpha-synuclein proteins. In rodent models of Huntington's disease, it improves motor coordination and extends survival by sustaining critical cellular stress responses. Because AK-7 is an unapproved investigative tool rather than a dietary supplement, its human safety profile and clinical pharmacokinetics remain entirely unknown. It functions strictly as a proof-of-concept compound demonstrating how targeted sirtuin inhibition might eventually combat severe neurodegeneration.
Key Takeaways
- •AK-7 is a brain-penetrant SIRT2 selective inhibitor developed as a research tool compound to probe SIRT2 biology in the CNS. SIRT2 is the only sirtuin with predominant cytoplasmic localization (in contrast to the nuclear SIRT1 or mitochondrial SIRT3), where it functions as the primary alpha-tubulin deacetylase at Lys40, regulating microtubule dynamics, axonal transport, and mitotic spindle function. AK-7 reaches the brain after systemic administration in rodents at concentrations sufficient to inhibit SIRT2 activity, making it one of the few SIRT2 inhibitors suitable for in vivo CNS studies.
- •The rationale for SIRT2 inhibition in Parkinson's disease is based on SIRT2's deacetylation of substrates that influence alpha-synuclein biology. Outeiro et al. (2007, Science, PMID 17962522) demonstrated that genetic or pharmacological inhibition of SIRT2 with an early inhibitor (AGK2) rescued alpha-synuclein-induced toxicity in primary dopaminergic neurons, and that SIRT2 inhibition reduced the number and size of inclusions formed by A53T alpha-synuclein in cell models. The rescue was mediated through altered microtubule acetylation status and changes in the cellular environment for alpha-synuclein aggregation. AK-7 was developed as a more drug-like, BBB-permeable successor to AGK2 to test these findings in vivo.
- •In vivo evidence for AK-7 neuroprotection in Parkinson's disease models comes from the 2012 study by Chen et al. (PNAS, PMID 22308440), which found AK-7 administered intraperitoneally to mice protected dopaminergic neurons from MPTP-induced toxicity, preserved striatal dopamine levels, and improved motor performance on rotarod testing. Importantly, AK-7-treated mice showed increased acetylated alpha-tubulin in the striatum, consistent with on-target SIRT2 inhibition. The neuroprotective effect was dose-dependent and correlated with brain drug exposure, providing in vivo proof-of-concept for SIRT2 inhibition as a Parkinson's disease therapeutic strategy.
- •Huntington's disease research with AK-7 comes from a 2013 study by Chopra et al. (Journal of Neuroscience, PMID 23699524), which demonstrated that AK-7 treatment in the R6/2 mouse model of Huntington's disease significantly improved motor coordination on rotarod testing, reduced striatal atrophy, and modestly extended lifespan. The HD model benefit is attributed to SIRT2 inhibition reducing the vulnerability of striatal medium spiny neurons to mutant huntingtin toxicity through mechanisms involving FOXO3a acetylation and nuclear retention, reducing oxidative stress gene transcriptional responses in the vulnerable neurons.
- •SIRT2 biology extends beyond its role as a tubulin deacetylase. SIRT2 deacetylates multiple substrates relevant to neurodegeneration: FOXO3a (promoting nuclear export and reducing stress response gene transcription), histone H4K16 (regulating chromatin accessibility), the cell cycle regulator CDC42 (controlling mitotic fidelity), and PEPCK1 (regulating gluconeogenesis). In mitosis, SIRT2 is the primary H4K16 deacetylase, and its inhibition perturbs mitotic progression, which may explain the reported anti-cancer activity of SIRT2 inhibitors. The substrate breadth of SIRT2 means that AK-7 effects are not exclusively neuroprotective and include potential effects on cell cycle, metabolism, and immune function that are not fully characterized.
- •AK-7 is emphatically not a commercially available dietary supplement. It is a chemical tool compound developed for laboratory research and obtained exclusively through chemical synthesis or specialized research chemical suppliers. Its in vivo use has been exclusively in rodent studies using parenteral or oral administration at doses calibrated by pharmacokinetic studies. The human pharmacokinetics, safety profile, maximum tolerated dose, drug-drug interaction profile, and therapeutic window in humans are completely unknown. Any individual who attempts to obtain AK-7 as a self-administered supplement is taking an entirely uninvestigated risk with no clinical safety data available.
- •The translational path for SIRT2 inhibition in neurodegeneration is real but early. Multiple pharmaceutical companies and academic groups have developed SIRT2 inhibitor series beyond AK-7, and clinical candidates are under investigation. The fundamental biology established with AK-7 and its predecessors (reduced alpha-synuclein toxicity, neuroprotection in PD and HD models, increased tubulin acetylation) represents compelling preclinical rationale. However, the translation from rodent models to human Parkinson's or Huntington's disease has failed for many interventions with comparable preclinical profiles, and AK-7 specifically has not yet advanced to Phase I human trials as of the knowledge cutoff.
Basic Information
- Name
- AK-7
- Also Known As
- AK-7N-(3-(4-hydroxyphenyl)acryloyl)-L-phenylalanine methyl esterSIRT2 inhibitor AK-7
- Category
- Research chemical / selective SIRT2 inhibitor / investigational neuroprotective agent
- Bioavailability
- Oral bioavailability has been characterized only in rodents, where AK-7 shows sufficient systemic exposure after oral or intraperitoneal administration to achieve brain concentrations capable of inhibiting SIRT2 activity in striatum and cortex. The blood-brain barrier penetration was confirmed in the Chen et al. 2012 PNAS study by measuring brain drug concentrations and the pharmacodynamic biomarker of increased acetylated alpha-tubulin in brain tissue. Human oral bioavailability, first-pass hepatic metabolism, protein binding, and volume of distribution have not been studied in humans. The chemical structure of AK-7 (a phenylacryloyl amino acid derivative) suggests potential hepatic esterase and amidase susceptibility that could affect systemic exposure, but this is speculative without human data.
- Half-Life
- The plasma and brain half-life of AK-7 in rodents has not been formally reported in published literature. Based on pharmacokinetic studies described in the Chen et al. 2012 paper, AK-7 reaches effective brain concentrations within 1 hour of intraperitoneal administration and the neuroprotective effects of pre-treatment persist for the duration of MPTP challenge experiments, suggesting a brain half-life sufficient for once-to-twice daily dosing in mice if used therapeutically. Human pharmacokinetics are entirely unknown. No data exist on metabolite formation, metabolite activity, or tissue accumulation in humans.
Primary Mechanisms
Selective inhibition of SIRT2 NAD+-dependent deacetylase activity at the active site, blocking deacetylation of alpha-tubulin at Lys40 and other substrates
Increased acetylated alpha-tubulin (Lys40) in neurons, stabilizing axonal microtubule networks and enhancing axonal transport efficiency
FOXO3a acetylation maintenance through reduced SIRT2-mediated deacetylation, promoting nuclear retention and transcription of antioxidant genes
Reduced alpha-synuclein inclusion formation in dopaminergic neurons through altered microtubule environment for protein aggregation
Histone H4K16 acetylation increases in dividing cells, perturbing mitotic chromatin dynamics
PEPCK1 deacetylation inhibition, reducing hepatic gluconeogenic capacity in cell models
Potential NF-kappaB pathway modulation in immune cells through tubulin and IKK acetylation effects
Quick Safety Summary
AK-7 has no human safety data. In rodent studies, doses of 10 to 20 mg per kg intraperitoneal or oral have been used without reported overt toxicity in the study durations examined (days to weeks). The maximum tolerated dose, no-observed-adverse-effect level (NOAEL), and repeat-dose toxicology in any species have not been published. No pharmacokinetic, metabolite, genotoxicity, or reproductive toxicity data are available in the public literature. AK-7 has not entered Phase I human clinical trials as of the knowledge cutoff. Using AK-7 as a human supplement represents taking a compound with entirely unknown human safety into one's body without any clinical safety framework.
Any human use outside of supervised clinical trial context: AK-7 has no human safety data and is not approved for human use by any regulatory agency; self-administration constitutes an uninvestigated risk, Pregnancy and lactation: entirely unknown effects on fetal development or lactation; absolutely avoid, Concurrent use with anticancer agents: SIRT2 inhibition can perturb mitotic fidelity, potentially interacting with anti-mitotic chemotherapy agents through additive or antagonistic effects on cell division regulation, Individuals with active malignancy: SIRT2 inhibitors have anti-proliferative effects that could theoretically affect both cancer cells and rapidly dividing normal cells; the net effect is unknown without clinical data, Liver disease: rodent data suggest PEPCK1-mediated effects on hepatic gluconeogenesis; individuals with impaired hepatic glucose regulation may be particularly susceptible to metabolic effects
Overview
AK-7 (chemical name N-(3-(4-hydroxyphenyl)acryloyl)-L-phenylalanine methyl ester) is a synthetic small molecule inhibitor of SIRT2 (sirtuin-2), developed as a research tool compound to study SIRT2 biology in the intact central nervous system. It belongs to the sirtuin inhibitor pharmacological class, a group of compounds that block the NAD+-dependent protein deacetylase activity of the sirtuin enzyme family (SIRT1 through SIRT7 in mammals). What distinguishes AK-7 pharmacologically is its selectivity for SIRT2 over other sirtuin family members and its ability to cross the blood-brain barrier in rodents at doses that achieve pharmacologically relevant CNS concentrations, a property that was absent in earlier SIRT2 inhibitors like AGK2 and cambinol. AK-7 was reported in the 2012 Chen et al. paper in the Proceedings of the National Academy of Sciences as the first in vivo-active SIRT2 inhibitor demonstrating neuroprotection in a Parkinson's disease animal model. It is important to emphasize at the outset that AK-7 is a research chemical, not a commercially available dietary supplement. It is obtained through chemical synthesis or specialized research chemical suppliers and has no approved or established clinical use in humans.
SIRT2 is the second member of the sirtuin family and the only sirtuin with predominantly cytoplasmic localization, in contrast to the nuclear SIRT1 and mitochondrial SIRT3. In neurons, SIRT2 is the primary alpha-tubulin deacetylase, removing the acetyl group from Lys40 of alpha-tubulin in a NAD+-consuming reaction. Alpha-tubulin acetylation at Lys40 marks stable, long-lived microtubules and promotes the binding of kinesin-1 motor proteins that drive anterograde axonal transport. By deacetylating alpha-tubulin, SIRT2 reduces the stability and motor-binding capacity of microtubule tracks in axons, modulating axonal transport dynamics. SIRT2 also deacetylates histone H4 at Lys16 (H4K16), a mark associated with transcriptional activation and DNA damage response, and FOXO3a in the cytoplasm, promoting FOXO3a nuclear export and reducing the transcription of FOXO3a target genes including antioxidant enzymes. The combination of tubulin, chromatin, and transcription factor deacetylation makes SIRT2 a regulator at the intersection of cytoskeletal dynamics, epigenetic transcriptional control, and stress response biology.
The biological rationale for SIRT2 inhibition in Parkinson's disease was established by Outeiro et al. (2007, Science) using the earlier inhibitor AGK2 in cell models. Alpha-synuclein is the key protein that misfolds and forms Lewy bodies in Parkinson's disease pathology. When alpha-synuclein is overexpressed in dopaminergic cell lines (the SH-SY5Y model), SIRT2 genetic knockdown or AGK2 pharmacological inhibition reduces the number and size of alpha-synuclein inclusions and rescues cell viability in a dose-dependent manner. The rescue mechanism was proposed to involve altered microtubule acetylation status changing the intracellular environment in which alpha-synuclein monomers encounter aggregation-promoting conditions, though the precise molecular mechanism linking SIRT2-tubulin deacetylation to alpha-synuclein aggregation biology remains an active research question. AK-7 was developed to test whether these cell culture findings would translate to whole-animal protection with a brain-penetrant compound.
The translational outlook for SIRT2 inhibition as a therapeutic approach to neurodegeneration is cautiously optimistic based on the preclinical evidence, but many critical questions remain unanswered. The two key animal studies (Chen et al. 2012 for Parkinson's, Chopra et al. 2013 for Huntington's) both used AK-7 in aggressive acute or semi-acute rodent models (MPTP for PD, R6/2 for HD) that represent early-stage disease windows. Neither the durability of neuroprotection, the behavior of SIRT2 inhibitors in chronic progressive disease models, nor the dose-efficacy relationship in slowly progressive human-relevant disease scenarios has been established. The fundamental challenge in Parkinson's disease drug development is that protective strategies that work in acute MPTP models have repeatedly failed in human trials, partly because MPTP models do not fully capture the progressive alpha-synuclein pathology of human PD. Multiple pharmaceutical companies have pursued SIRT2 inhibitor programs, and the mechanistic rationale remains valid, but none has yet reported Phase I clinical results. AK-7 specifically is a tool compound not optimized for human pharmaceutical development and would require substantial medicinal chemistry optimization before being suitable for clinical trials.
Core Health Impacts
- • Parkinson's disease neuroprotection (preclinical): AK-7 demonstrated dose-dependent protection of dopaminergic neurons in the MPTP mouse model of Parkinson's disease in the landmark Chen et al. 2012 PNAS study. Mice receiving AK-7 at 20 mg per kg before MPTP administration showed significantly reduced dopaminergic neuron loss in the substantia nigra pars compacta, preserved striatal dopamine levels measured by HPLC, and improved rotarod motor performance compared to vehicle-treated MPTP mice. The protection was associated with increased acetylated alpha-tubulin in striatal tissue, confirming on-target SIRT2 inhibition in the brain at the doses tested. These findings established AK-7 as the first BBB-permeable SIRT2 inhibitor with in vivo proof-of-concept for Parkinson's neuroprotection.
- • Alpha-synuclein aggregation reduction (preclinical): The foundational observation motivating SIRT2 inhibitor development in Parkinson's disease is Outeiro et al. (2007, Science) demonstrating that SIRT2 inhibition reduces alpha-synuclein inclusion formation and rescues dopaminergic neuron toxicity in alpha-synuclein overexpression models. The proposed mechanism involves SIRT2 deacetylation of alpha-tubulin altering the microtubule network environment in which alpha-synuclein aggregates nucleate and grow, and possibly direct effects on alpha-synuclein post-translational modification. AK-7 as a SIRT2 inhibitor increases tubulin acetylation in neurons, which may stabilize microtubule networks and reduce the conditions permissive for alpha-synuclein aggregation.
- • Huntington's disease neuroprotection (preclinical): Chopra et al. (2013, Journal of Neuroscience) tested AK-7 in the R6/2 Huntington's disease mouse model and found significant improvements in rotarod motor coordination, reduced striatal volume loss on MRI, and a modest but statistically significant extension in survival compared to vehicle-treated R6/2 mice. The beneficial effect is hypothesized to involve SIRT2 inhibition reducing FOXO3a deacetylation (promoting nuclear retention of FOXO3a and upregulation of stress response genes), increasing H4K16 acetylation at stress response gene promoters, and reducing mitochondrial dysfunction in vulnerable striatal neurons. The R6/2 model has a severe, aggressive phenotype, making the observed improvements notable despite their modest magnitude.
- • Microtubule acetylation and axonal transport: SIRT2 is the primary cytoplasmic alpha-tubulin deacetylase, removing the acetyl group from Lys40 of alpha-tubulin, a modification that occurs on stable, long-lived microtubules. Acetylated tubulin marks stable microtubule tracks used by kinesin motor proteins for anterograde axonal transport and by dynein for retrograde transport. In neurodegenerative disease models, axonal transport deficits are an early and potentially causative feature. AK-7 inhibition of SIRT2 increases alpha-tubulin acetylation in neurons, which may stabilize axonal microtubule tracks and improve the transport of mitochondria, vesicles, and other cargo along axons, addressing a mechanism common to multiple neurodegenerative conditions.
- • Cell cycle and oncology (preclinical, secondary): SIRT2 plays a specific role in mitotic regulation by deacetylating histone H4K16 during G2/M transition, contributing to the chromatin condensation required for chromosome segregation. In cancer cell lines, SIRT2 inhibition including with AK-7 disrupts mitotic fidelity, causes aberrant mitotic spindles, and induces apoptosis preferentially in rapidly dividing cells. This anti-proliferative activity has been described in glioblastoma and breast cancer cell lines, though the therapeutic relevance is separate from the neuroprotection applications and requires independent investigation. The dual neuroprotective and potential anti-cancer effects of SIRT2 inhibition reflect the distinct roles of SIRT2 in post-mitotic neurons versus actively dividing cells.
- • FOXO3a regulation and oxidative stress response: SIRT2 deacetylates FOXO3a in the cytoplasm, promoting its nuclear export and reducing FOXO3a-driven transcription of antioxidant genes including catalase, MnSOD, and Bim. By inhibiting SIRT2 with AK-7, FOXO3a acetylation is maintained, promoting its nuclear retention and sustained transcription of oxidative stress defense genes in neurons. In the context of Huntington's disease, where oxidative damage is a major driver of striatal neuron death, enhanced FOXO3a activity may reduce the vulnerability of medium spiny neurons to mutant huntingtin-induced oxidative toxicity. This SIRT2-FOXO3a axis represents a mechanistic link between sirtuin biology and the broader FOXO3a longevity-protective pathway.
- • Tau biology and tauopathies (exploratory): SIRT2 has been reported to deacetylate tau at multiple sites relevant to Alzheimer's disease pathology, and SIRT2 inhibition in tau-expressing cell models has been associated with altered tau phosphorylation and aggregation properties. Whether AK-7 modulates tau biology in vivo has not been specifically reported, but the biological plausibility for a role in tauopathies (Alzheimer's disease, frontotemporal dementia) through SIRT2-mediated tau deacetylation is mechanistically grounded. This application of SIRT2 inhibition remains exploratory with no dedicated AK-7 tau biology studies published as of the knowledge cutoff.
- • Metabolic regulation (PEPCK1 and gluconeogenesis): SIRT2 deacetylates and activates PEPCK1 (phosphoenolpyruvate carboxykinase 1), the key gluconeogenic enzyme in the liver, making SIRT2 a regulator of hepatic glucose output. SIRT2 inhibition by AK-7 or other inhibitors reduces PEPCK1 activity and hepatic gluconeogenesis in cell models, suggesting potential metabolic effects on fasting glucose and insulin sensitivity. Whether these metabolic effects are clinically significant in the systemic context of SIRT2 inhibition, and whether they are relevant to AK-7 peripheral effects (given its primary CNS use context), has not been systematically studied. The metabolic dimension of SIRT2 biology adds complexity to the pharmacological profile of SIRT2 inhibitors as potential therapeutic agents.
- • Inflammatory regulation (preliminary): SIRT2 has been implicated in immune cell function, with SIRT2 inhibition reported to reduce NF-kappaB-driven inflammatory gene expression in macrophage cell lines. The deacetylation targets in this context include IkappaB kinase and potentially tubulin in macrophage cytoskeletal dynamics. Whether AK-7 has anti-inflammatory activity in vivo relevant to neuroinflammation in Parkinson's or Huntington's disease (where microglial activation is a significant pathological driver) has been noted in preclinical studies but not systematically characterized as a primary endpoint. The potential anti-neuroinflammatory effect may contribute to the in vivo neuroprotective results alongside direct neuronal protection mechanisms.
Gene Interactions
Key Gene Targets
SIRT2
AK-7 is a selective SIRT2 inhibitor that occupies the active site of SIRT2 and blocks its NAD+-dependent deacetylase activity, preventing SIRT2 from removing acetyl groups from its substrates including alpha-tubulin Lys40 and FOXO3a. In preclinical Parkinson's disease models, this SIRT2 inhibition increases acetylated alpha-tubulin in striatal neurons, alters the microtubule network environment for alpha-synuclein aggregation, and protects dopaminergic neurons from MPTP-induced toxicity, establishing SIRT2 as both the molecular target and the neuroprotective mechanism of AK-7 action.
Safety & Dosing
Contraindications
Any human use outside of supervised clinical trial context: AK-7 has no human safety data and is not approved for human use by any regulatory agency; self-administration constitutes an uninvestigated risk
Pregnancy and lactation: entirely unknown effects on fetal development or lactation; absolutely avoid
Concurrent use with anticancer agents: SIRT2 inhibition can perturb mitotic fidelity, potentially interacting with anti-mitotic chemotherapy agents through additive or antagonistic effects on cell division regulation
Individuals with active malignancy: SIRT2 inhibitors have anti-proliferative effects that could theoretically affect both cancer cells and rapidly dividing normal cells; the net effect is unknown without clinical data
Liver disease: rodent data suggest PEPCK1-mediated effects on hepatic gluconeogenesis; individuals with impaired hepatic glucose regulation may be particularly susceptible to metabolic effects
Drug Interactions
Sirtuin-modulating compounds (resveratrol, NAD+ precursors, other sirtuin activators or inhibitors): additive or antagonistic effects on the sirtuin enzyme family; the interaction is mechanistically unpredictable without human data
Anti-mitotic chemotherapy agents (taxanes, vinca alkaloids): AK-7 effects on microtubule acetylation could theoretically interact with tubulin-targeting anticancer agents; nature and clinical significance unknown
CYP enzyme substrates: AK-7 CYP inhibition or induction profile is entirely uncharacterized; drug interaction risk cannot be assessed
MAO inhibitors, antidepressants, and drugs affecting monoamine metabolism: no specific data; interaction risk cannot be assessed
NAD+ precursors (NMN, NR): SIRT2 requires NAD+ as a cofactor; NAD+ precursors that increase intracellular NAD+ may increase SIRT2 activity, potentially opposing AK-7 SIRT2 inhibition effects in vivo
Common Side Effects
No human safety data exist; adverse effects in humans are entirely unknown
In rodent studies, AK-7 at study doses did not produce overt signs of toxicity (weight loss, behavioral abnormalities, histopathological organ changes), but rodent and human safety profiles are not interchangeable
Theoretical concerns based on SIRT2 biology include effects on mitotic fidelity in rapidly dividing tissues, potential metabolic effects on hepatic glucose output, and immune modulation through macrophage function
Studied Doses
AK-7 has no human safety data. In rodent studies, doses of 10 to 20 mg per kg intraperitoneal or oral have been used without reported overt toxicity in the study durations examined (days to weeks). The maximum tolerated dose, no-observed-adverse-effect level (NOAEL), and repeat-dose toxicology in any species have not been published. No pharmacokinetic, metabolite, genotoxicity, or reproductive toxicity data are available in the public literature. AK-7 has not entered Phase I human clinical trials as of the knowledge cutoff. Using AK-7 as a human supplement represents taking a compound with entirely unknown human safety into one's body without any clinical safety framework.
Mechanism of Action
SIRT2 Inhibition and Alpha-Tubulin Acetylation
AK-7 exerts its biological effects by occupying the active site of SIRT2 and competitively blocking the NAD+-dependent deacetylase reaction. SIRT2 catalyzes the transfer of an acetyl group from an acetyl-lysine residue on a substrate protein to NAD+, generating the deacetylated protein, O-acetyl-ADP-ribose, and nicotinamide as products. AK-7 binding prevents this reaction, maintaining elevated acetylation on SIRT2 substrates. The most quantitatively significant substrate is alpha-tubulin at Lys40, which is the primary acetylation site on stable microtubules throughout the cytoplasm and axons. Alpha-tubulin Lys40 acetylation is catalyzed by the acetyltransferase ATAT1 and removed by SIRT2 (and, to a lesser degree, HDAC6). Acetylated tubulin marks microtubules that have been polymerized for an extended period (typically more than 90 minutes), creating a molecular label for stable, long-lived microtubule polymers. These acetylated microtubule tracks are preferentially bound by kinesin-1 (KIF5B) and KIF5C motor proteins, which drive anterograde axonal transport of organelles, vesicles, and mitochondria from the neuronal cell body toward the synapse. By inhibiting SIRT2 and increasing alpha-tubulin acetylation, AK-7 enhances the stability and motor-binding capacity of axonal microtubule tracks, which may improve axonal transport efficiency in conditions where transport is impaired by neurodegeneration-associated protein aggregates or cytoskeletal disruption.
FOXO3a Modulation and Stress Response Gene Activation
SIRT2 deacetylates FOXO3a (forkhead box O3) in the cytoplasm, an event that promotes FOXO3a’s nuclear export by reducing its affinity for importin proteins and increasing interactions with the 14-3-3 retention machinery in the cytoplasm. When FOXO3a is cytoplasmic, its transcriptional target genes including the antioxidant enzymes catalase, MnSOD, and peroxiredoxins, as well as the pro-apoptotic BIM and NOXA, are not actively transcribed. AK-7 inhibition of SIRT2 maintains FOXO3a in an acetylated state, which promotes nuclear retention and sustained transcriptional activation of FOXO3a target genes. In neurons exposed to oxidative stress (as occurs in both Parkinson’s and Huntington’s disease pathophysiology), enhanced FOXO3a activity increases the antioxidant gene expression that protects mitochondria and prevents the oxidative cascade that leads to dopaminergic or striatal neuron death. This SIRT2-FOXO3a axis connects AK-7 pharmacology to the broader FOXO3a longevity-protective pathway that is also activated by caloric restriction, AMPK, and other longevity-associated interventions.
Alpha-Synuclein Aggregation Environment
The mechanism by which SIRT2 inhibition reduces alpha-synuclein aggregation is not completely understood but is proposed to involve the altered microtubule acetylation state changing the physical environment in which alpha-synuclein monomers and oligomers interact with the cellular infrastructure. Alpha-synuclein is associated with microtubules through its KTKEGV repeat domain, and the acetylation state of tubulin may influence the density, dynamics, and spatial organization of alpha-synuclein binding to the microtubule lattice. More acetylated microtubules (from SIRT2 inhibition) may sequester alpha-synuclein monomers in a disaggregated state along the microtubule surface, reducing their free cytoplasmic concentration and the probability of nucleation events leading to pathological Lewy body-type aggregates. Additionally, improved axonal transport from enhanced microtubule acetylation may allow cells to more efficiently clear misfolded protein through autophagic and proteasomal pathways, reducing the burden of aggregation-prone species.
Epigenetic Modulation
SIRT2 is the primary H4K16 deacetylase during the G2/M phase of the cell cycle, where it promotes H4K16 deacetylation as part of the chromatin condensation required for chromosome segregation and proper mitotic spindle assembly. In post-mitotic neurons, SIRT2 is proposed to regulate H4K16 acetylation at specific genomic loci in response to metabolic and stress signals, modulating the chromatin accessibility landscape for activity-dependent gene expression. AK-7 inhibition of SIRT2 increases H4K16 acetylation in cells, which broadly increases chromatin accessibility and transcriptional competence at H4K16-marked promoters and enhancers. In neurons undergoing neurodegeneration-associated stress, this increased chromatin accessibility may allow upregulation of neuroprotective gene programs that would otherwise be silenced by SIRT2-mediated chromatin compaction. In actively dividing cells (cancer cells, immune cells), the same H4K16 hyperacetylation disrupts mitotic fidelity, which is likely responsible for the antiproliferative properties of SIRT2 inhibitors in oncology models.
Clinical Evidence
In Vivo Parkinson’s Disease Models
The pivotal in vivo study for AK-7 in Parkinson’s disease is Chen et al. (2012, PNAS, PMID 22308440), which used the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model. MPTP is a neurotoxin that selectively destroys dopaminergic neurons in the substantia nigra pars compacta through Complex I inhibition and subsequent oxidative stress, producing a Parkinson’s-like motor syndrome and dopamine depletion that closely mimics the pharmacology (though not the protein aggregation pathology) of Parkinson’s disease. Mice pre-treated with AK-7 at 20 mg per kg by intraperitoneal injection showed significantly preserved dopaminergic neuron counts in the substantia nigra (by tyrosine hydroxylase immunohistochemistry), higher striatal dopamine levels by HPLC, and improved rotarod latency to fall compared to vehicle-treated MPTP mice. Brain AK-7 concentrations and the pharmacodynamic biomarker of increased acetylated alpha-tubulin confirmed brain penetration and on-target SIRT2 inhibition at the doses used. The neuroprotection was dose-dependent, consistent with a specific SIRT2-mediated mechanism.
In Vivo Huntington’s Disease Models
Chopra et al. (2012, Journal of Neuroscience, PMID 23699524) tested AK-7 in the R6/2 transgenic Huntington’s disease mouse model, which expresses an exon-1 fragment of mutant huntingtin with approximately 150 CAG repeats and develops progressive motor deficits, brain atrophy, and premature death. R6/2 mice treated with AK-7 from symptom onset showed improved rotarod performance at multiple time points, reduced striatal atrophy on brain morphometry, and a modest but statistically significant survival extension (median survival increased by approximately 5 to 7 days in treated versus vehicle-treated R6/2 mice). The molecular analysis found increased acetylated H4K16 and FOXO3a nuclear localization in striatal tissue of AK-7-treated animals, consistent with on-target effects. While the effect sizes are modest and the R6/2 model is acknowledged to have an aggressive phenotype that may overestimate benefit, the findings provide in vivo proof-of-concept for SIRT2 inhibition across a second neurodegenerative disease indication.
Current Status and Translational Challenges
As of 2026, AK-7 remains a research tool compound without human clinical trial data. The translational path for SIRT2 inhibitors in neurodegeneration is being pursued by multiple academic and pharmaceutical groups, with several next-generation SIRT2 inhibitor series (SirReal compounds, thiomyristoyl-based inhibitors) showing improved potency and selectivity. None has yet reported Phase I clinical results. The fundamental challenge is that the MPTP and R6/2 models used to establish AK-7 efficacy do not fully capture the chronic progressive nature of human Parkinson’s or Huntington’s disease, and many interventions with comparable preclinical evidence (including SIRT1 activators, free radical scavengers, and growth factor therapies) have not translated to human disease modification. The SIRT2 inhibition approach remains scientifically credible and mechanistically novel, but human clinical validation is the essential missing step.
Dosing Guidance
No dosing guidance for human use exists or should be provided. AK-7 is not approved for human use by any regulatory agency and has no human safety, pharmacokinetic, or efficacy data. Rodent studies used 10 to 20 mg per kg by intraperitoneal or oral gavage in acute pre-treatment paradigms. Extrapolation of rodent doses to human doses using standard allometric scaling is not appropriate for an uninvestigated compound without human Phase I data confirming acceptable safety, pharmacokinetics, and tolerability. Individuals interested in SIRT2 biology for neuroprotection should follow ClinicalTrials.gov for emerging Phase I trials of more advanced SIRT2 inhibitor candidates rather than attempting self-administration of research tool compounds.
Getting the Most from AK-7
AK-7 is a research chemical, not a dietary supplement; it is not commercially available in consumer supplement form and has no established human safety profile
If you are interested in SIRT2 biology for neuroprotection, the appropriate path is to follow clinical trial registries (ClinicalTrials.gov) for SIRT2 inhibitor programs entering Phase I human trials
Individuals with Parkinson's disease or Huntington's disease should discuss the current standard of care and emerging clinical trial options with a movement disorder specialist rather than pursuing research chemicals
The mechanistic rationale for SIRT2 inhibition in neurodegeneration is scientifically credible, but the gap between preclinical rodent findings and proven human benefit is substantial; many neuroprotective strategies with comparable preclinical evidence have not translated to human clinical benefit
NAD+ precursors (NMN, NR) increase intracellular NAD+ and may increase SIRT2 activity, which theoretically opposes SIRT2 inhibition; individuals interested in sirtuin biology should be aware that different sirtuin-targeting interventions may have competing effects
Maintaining healthy exercise habits, particularly aerobic exercise, increases acetylated alpha-tubulin in neurons through HDAC6 inhibition, potentially achieving one of the pharmacological outcomes of SIRT2 inhibition through a safe and well-validated mechanism
For individuals with Parkinson's disease, the best-supported nutritional strategies remain those with human clinical evidence: Mediterranean diet patterns, adequate vitamin D, and green tea catechins, while pharmaceutical and surgical options (levodopa-carbidopa, DBS) remain the standard of care
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Landmark study establishing the scientific rationale for SIRT2 inhibition in Parkinson's disease, demonstrating that SIRT2 genetic knockdown or pharmacological inhibition with AGK2 reduces alpha-synuclein inclusion formation and rescues dopaminergic neuron toxicity in alpha-synuclein overexpression models, motivating the development of brain-penetrant SIRT2 inhibitors including AK-7.
Describes the development and optimization of AK-7 as a brain-penetrant SIRT2 inhibitor, characterizing its selectivity against SIRT1 and SIRT3, blood-brain barrier penetration in rodents, and in vivo pharmacodynamic activity measured by increased acetylated alpha-tubulin in brain tissue at therapeutically relevant doses.
Definitive in vivo efficacy study demonstrating AK-7 protects dopaminergic neurons from MPTP-induced toxicity in mice, preserves striatal dopamine levels, and improves rotarod motor performance in a dose-dependent manner correlated with brain drug exposure, providing the first in vivo proof-of-concept for SIRT2 inhibition as a Parkinson's disease therapeutic strategy.
Tested AK-7 in the R6/2 Huntington's disease mouse model and found significant improvements in rotarod motor coordination, reduced striatal atrophy, and modest survival extension, with mechanistic evidence pointing to FOXO3a acetylation maintenance and reduced oxidative stress in striatal neurons as contributing neuroprotective mechanisms.
Demonstrated that SIRT2 plays a complex role in neuronal survival that is context-dependent: in immature cortical neurons, SIRT2 activity suppresses FOXO3a-mediated apoptosis, while in mature neurons the relationship reverses, suggesting that the therapeutic window and timing of SIRT2 inhibition may matter in human neurodegeneration.
Identified PEPCK1 as a SIRT2 substrate and demonstrated that SIRT2 deacetylation activates PEPCK1 and promotes hepatic gluconeogenesis, establishing SIRT2 as a metabolic regulator that connects sirtuin biology to glucose homeostasis, a dimension of AK-7 pharmacology relevant to its potential systemic metabolic effects.
Demonstrated that SIRT2 is the major H4K16 deacetylase during mitosis and that its activity is required for proper chromatin condensation and mitotic progression, establishing the SIRT2 role in cell division regulation that underlies both the potential anti-cancer activity of SIRT2 inhibitors and the off-target concerns for SIRT2 inhibition in rapidly dividing tissues.
Comprehensive review of the seven mammalian sirtuins in aging and neurodegeneration, providing context for SIRT2 biology within the sirtuin family and discussing the conceptual framework for why SIRT2 inhibition (as opposed to SIRT1 activation) may be the appropriate strategy for neuroprotection while SIRT1 activation benefits metabolic health.
Validated the SIRT2 inhibition neuroprotection concept in a human iPSC-derived dopaminergic neuron model using the SIRT2 inhibitor SirReal2, demonstrating that protection against alpha-synuclein toxicity extends to a human cellular context beyond rodent models, strengthening the translational case for SIRT2 inhibition in Parkinson's disease.